Presenting prevalence, characteristics and outcome of asthmatic patients with T2 diseases in hospitalized subjects with COVID-19 in Madrid, Spain SUPPLEMENT Introduction. The first confirmed case of coronavirus disease 2019 (COVID-19) in Spain was reported in Madrid at the end of February 2020. Soon after, Madrid reported an outbreak, and cases in Spain increased dramatically, as one of the countries had more cases in the world. Material and Methods. Demographic data, smoking status, non-atopic comorbidities, presence of atopy, symptoms, clinical, radiological and laboratory data on-admission and discharge, need of ICU (Intensive Care Unit) admission days of hospitalization and death were analyzed. Severity of COVID-19 on-admission was classified according to the FIO 2 required: A0 (FIO 2 21%), A1 (FIO 2 up to 35%), A2 (35% >FIO 2 ≤60%) and A3 (FIO 2 > 60%). For asthmatic patients, data related to severity [9], treatment, compliance, and control before COVID-19 were collected together with exacerbation during hospitalization. Compliance was based on refill medication data on electronic prescription during the last year, good compliance was considered as  80% of refills. Asthmatic patients were categorized as non-allergic and allergic (by positive prick test to aeroallergens).

BackgroundStudies on the role of eosinophils in coronavirus disease 2019 (COVID-19) are scarce, though available findings suggest a possible association with disease severity. Our study analyzes the relationship between eosinophils and COVID-19, with a focus on disease severity and patients with underlying chronic respiratory diseases.MethodsWe performed a retrospective analysis of 3018 subjects attended at two public hospitals in Madrid (Spain) with PCR-confirmed SARS-CoV-2 infection from January 31 to April 17, 2020. Patients with eosinophil counts less than 0.02×109/L were considered to have eosinopenia. Individuals with chronic respiratory diseases (n=384) were classified according to their particular underlying condition, i.e., asthma, chronic pulmonary obstructive disease, or obstructive sleep apnea.ResultsOf the 3018 patients enrolled, 479 were excluded because of lack of information at the time of admission. Of 2539 subjects assessed, 1396 patients presented an eosinophil count performed on admission, revealing eosinopenia in 376 cases (26.93%). Eosinopenia on admission was associated with a higher risk of intensive care unit (ICU) or respiratory intensive care unit (RICU) admission (OR:2.21; 95%CI:1.42-3.45; p<0.001) but no increased risk of mortality (p>0.05).ConclusionsEosinopenia on admission conferred a higher risk of severe disease (requiring ICU/RICU care), but was not associated with increased mortality. In patients with chronic respiratory diseases who develop COVID-19, age seems to be the main risk factor for progression to severe disease or death.

No abstract

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as

Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory respiratory disorder with a significant deleterious impact on quality of life. Intranasal corticosteroids (INCS) and saline irrigation are the mainstay treatment [1].